Company intelligence / Profile preview

Cygnus Biosciences

Ownership: Private
Development stage: Preclinical

Overview

Cygnus Biosciences develops and commercializes advanced gene sequencing technologies. The company specializes in synthesizing fluorogenic dyes and has developed proprietary error-correction code sequencing platforms. Its products are used in life science research as well as diagnostic applications across medical research, environmental safety, and food safety sectors. The company holds several patents related to DNA/RNA preparation methods.

Therapeutic areas: OtherInfectious Diseases
Modalities: Sequencing technologiesfluorogenic dyeserror-correction code sequencing
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Cygnus Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cygnus Biosciences.

Explore the full profile